Progenics preclinical data

Results from Progenics' preclinical study of three monoclonal antibodies demonstrated that PRO-542 (CD4-IgG2) was the most effective in neutralizing all clinical isolates of HIV in vitro, including isolates from different genetic virus strains ubiquitous in the U.S., Europe, and elsewhere. The study was published in the Journal of Virology.

The compound is being developed as an immunotherapy for individuals who are HIV-infected, for use alone or in combination with antivirals, and as preventive therapy to protect exposed individuals from contracting the virus by reducing the concentration of HIV in the bloodstream. ...